How I treat enteropathy-associated T-cell lymphoma

Blood

Volumn 119, Issue 11, 2012, Pages 2458-2468

  Di Sabatino, Antonio ^a   Biagi, Federico ^a   Gobbi, Paolo G ^a   Corazza, Gino R ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMG 714; BLEOMYCIN; CHLORMETHINE; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ENEMA; ETOPOSIDE; GEMCITABINE; HLA DQ2 ANTIGEN; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ABDOMINAL PAIN; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RADIOTHERAPY; CANCER STAGING; CELIAC DISEASE; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENDOSCOPY; ENTEROPATHY ASSOCIATED T CELL LYMPHOMA; FEVER; GENETIC ASSOCIATION; GLUTEN FREE DIET; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; MAGNETIC RESONANCE ENTEROCLYSIS; NIGHT SWEAT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; SURVIVAL TIME; WEIGHT REDUCTION;

EID: 84858653535     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-385559     Document Type: Review

References (92)

1. Di Sabatino A, Corazza GR. Coeliac disease. Lancet. 2009;373(9785):1480- 1493.
2. Biagi F, Corazza GR. Mortality in celiac disease. Nat Rev Gastroenterol Hepatol. 2010;7(3):158-162.
3. Biagi F, Corazza GR. Defining "gluten refractory enteropathy." Eur J Gastroenterol Hepatol. 2001;13(5):561-565.
4. Malamut G, Cellier C. Is refractory celiac disease more severe in old Europe? Am J Gastroenterol. 2011;106(5):929-932.
5. West J. Celiac disease and its complications: a time traveller's perspective. Gastroenterology. 2009;136(1):32-34.
6. Roshan B, Leffler DA, Jamma S, et al. The incidence and clinical spectrum of refractory celiac disease in a north American referral center. Am J Gastroenterol. 2011;106(5):923-928.
7. Malamut G, Afchain P, Verkarre V, et al. Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology. 2009;136(1):81-90.
8. Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007;56(10):1373- 1378. (Pubitemid 47517830)
9. Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M, Ullrich R. High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol. 2009;21(1):66-70.
10. Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ, Coupé VM. Incidence of enteropathy-associated T-cell lymphoma: a nationwide study of a population-based registry in The Netherlands. Scand J Gastroenterol. 2008;43(11):1322-1328.
11. Shack LG, Wood HE, Kang JY, et al. Small intestinal cancer in England & Wales and Scotland: time trends in incidence, mortality and survival. Aliment Pharmacol Ther. 2006;23(9):1297-1306.
12. Rubio-Tapia A, Murray JA. Classification and management of refractory coeliac disease. Gut. 2010;59(4):547-557.
13. Smedby KE, Akerman M, Hildebrand H, Glimelius B, Ekbom A, Askling J. Malignant lymphomas in coeliac disease: evidence of increased risks for lymphoma types other than enteropathytype T cell lymphoma. Gut. 2005;54(1):54-59. (Pubitemid 40007218)
14. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am J Med. 2003;115(3):191-195. (Pubitemid 37338143)
15. Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, Murray JA. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology. 2009;136(1):99-107.
16. Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol. 2000;18(4):795-803. (Pubitemid 30106610)
17. Gough KR, Read AE, Naish JM. Intestinal reticulosis as a complication of idiopathic steatorrhoea. Gut. 1962;3:232-239.
18. Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007;132(5):1902-1911. (Pubitemid 46677947)
19. Biagi F, Bianchi PI, Vattiato C, et al. Influence of HLA-DQ2 and DQ8 on severity in celiac disease. J Clin Gastroenterol. 2012;46(1):46-50.
20. Biagi F, Poggioli G, Mazzoni G, Corazza GR. Intestinal strictures. Lancet. 1998;352(9131):876. (Pubitemid 28416723)
21. Biagi F, Lorenzini P, Corazza GR. Literature review on the clinical relationship between ulcerative jejunoileitis, coeliac disease and enteropathy associated T cell lymphoma. Scand J Gastroenterol. 2000;35(8):785-790.
22. Mention JJ, Ben Ahmed M, Bègue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology. 2003;125(3):730-745. (Pubitemid 37070691)
23. Di Sabatino A, Ciccocioppo R, Cupelli F, et al. Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut. 2006;55(4):469-477.
24. Malamut G, El Machhour R, Montcuquet N, et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest. 2010;120(6):2131-2143.
25. Domizio P, Owen RA, Shepherd NA, Talbot IC, Norton AJ. Primary lymphoma of the small intestine: a clinicopathological study of 119 cases. Am J Surg Pathol. 1993;17(5):429-442. (Pubitemid 23121773)
26. Hovenga S, de Graaf H, Joosten P, et al. Enteropathy-associated T-cell lymphoma presenting with eosinophilia. Neth J Med. 2003;61(1):25-27. (Pubitemid 39106989)
27. McBride OM, Skipworth RJ, Leitch D, Yalamarthi S. Cavitating mesenteric lymph node syndrome in association with coeliac disease and enteropathy associated T-cell lymphoma: a case report and review of the literature. Case Report Med. 2010;2010:478269.
28. Di Sabatino A, Rosado MM, Cazzola P, et al. Splenic hypofunction and the spectrum of autoimmune and malignant complications in celiac disease. Clin Gastroenterol Hepatol. 2006;4(2):179-186. (Pubitemid 43199688)
29. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic state. Lancet. 2011;378(9785):86-97.
30. Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397-400. (Pubitemid 24159642)
31. Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep. 2006;16(1):191-195.
32. Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie. 1977;153(4):218-221. (Pubitemid 8097721)
33. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
34. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148-155.
35. de Baaij LR, van de Water JM, Verbeek WH, et al. Enteropathy associated T-cell lymphoma: a clinical prognostic model to identify high risk patients. Gastroenterology. 2011;140(suppl 1):A151.
36. Leighton JA. The role of endoscopic imaging of the small bowel in clinical practice. Am J Gastroenterol. 2011;106(1):27-36.
37. Al-Toma A, Verbeek WH, Mulder CJ. The management of complicated celiac disease. Dig Dis. 2007;25(3):230-236. (Pubitemid 350194174)
38. Mallant M, Hadithi M, Al-Toma AB, et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol. 2007;13(11):1696-1700. (Pubitemid 46711340)
39. Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med. 2006;47(10):1622-1627. (Pubitemid 47545027)
40. Hoffmann M, Vogelsang H, Kletter K, Zettinig G, Chott A, Raderer M. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. Gut. 2003;52(3):347-351. (Pubitemid 36250052)
41. Laird J, Leach M, Ballantyne S. The value of small bowel magnetic resonance imaging in the management of enteropathy associated T-cell lymphoma. Br J Haematol. 2008;142(1):136-137. (Pubitemid 351783142)
42. Van Weyenberg SJ, Meijerink MR, Jacobs MA, van Kuijk C, Mulder CJ, van Waesberghe JH. MR enteroclysis in refractory celiac disease: proposal and validation of a severity scoring system. Radiology. 2011;259(1):151-161.
43. Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy. 2007;39(5):455-458. (Pubitemid 46785085)
44. Hadithi M, Al-Toma A, Oudejans J, van Bodegraven AA, Mulder CJ, Jacobs M. The value of double-balloon enteroscopy in patients with refractory celiac disease. Am J Gastroenterol. 2007;102(5):987-996. (Pubitemid 46698230)
45. Matsumoto T, Nakamura S, Esaki M, et al. Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma. Dig Dis Sci. 2010;55(1):158-165.
46. de Bruin PC, Connolly CE, Oudejans JJ, et al. Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype. Histopathology. 1997;31(4):313-317. (Pubitemid 27448910)
47. Bagdi E, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood. 1999;94(1):260-264. (Pubitemid 29300157)
48. Verbeek WH, Goerres MS, von Blomberg BM, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. Clin Immunol. 2008;126(1):48-56. (Pubitemid 350266454)
49. Murray A, Cuevas D, Jones B, Wright DH. Study of the immunohistochemistry and T-cell clonality of enteropathy associated T-cell lymphoma. Am J Pathol. 1995;146(2):509-519.
50. Isaacson PG, O'Connor NTG, Spencer J, et al. Malignant histiocytosis of the intestine: AT-cell lymphoma. Lancet. 1985;2(8457):688-691. (Pubitemid 15244945)
51. Daum S, Weiss D, Hummel M, et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut. 2001;49(6):804-812. (Pubitemid 33096038)
52. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. Lancet. 2000;356(9225):203-208. (Pubitemid 30446975)
53. Patey-Mariaud D, Serre N, Cellier C, et al. Distinction between coeliac disease and refractory sprue: a simple immunohistochemical method. Histopathology. 2000;37(1):70-77.
54. Al-Toma A, Goerres MS, Meijer JW, Peña AS, Crusius JB, Mulder CJ. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol. 2006;4(3):315-319. (Pubitemid 43343887)
55. Wolters VM, Verbeek WH, Zhernakova A, et al. The MYO9B gene is a strong risk factor for developing refractory celiac disease. Clin Gastroenterol Hepatol. 2007;5(12):1399-1405.
56. Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol. 2002;161(5):1635-1645. (Pubitemid 35265523)
57. Baumgärtner AK, Zettl A, Chott A, Ott G, Müller-Hermelink HK, Starostik P. High frequency of genetic aberrations in enteropathy-type T-cell lymphoma. Lab Invest. 2003;83(10):1509-1516. (Pubitemid 37267834)
58. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal Non-Hodgkin's Lymphoma. J Clin Oncol. 2003;21(14):2740-2746. (Pubitemid 46606320)
59. Raderer M, Troch M, Kiesewetter B, et al. Second line chemotherapy in patients with enteropathy-associated T cell lymphoma: a retrospective single center analysis. Ann Hematol. 2012;91(1):57-61.
60. Ferreri AJ, Zinzani PL, Govi S, Pileri SA. Enteropathy-associated T-cell lymphoma. Crit Rev Oncol Hematol. 2011;79(1):84-90.
61. Hönemann D, Prince HM, Hicks RJ, Seymour JF. Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options. Ann Hematol. 2005;84(2):118-121. (Pubitemid 40089769)
62. Egan LJ, Walsh SV, Stevens FM, Connolly CE, Egan EL, McCarthy CF. Celiac-associated lymphoma: a single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol. 1995;21(2):123-129.
63. Wöhrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004;15(11):1680-1683. (Pubitemid 39562610)
64. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664-3670.
65. Jantunen E, Juvonen E, Wiklund T, Putkonen M, Nousiainen T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma. 2003;44(12):2163-2164. (Pubitemid 37369662)
66. Bishton MJ, Haynes AP. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol. 2007;136(1):111-113. (Pubitemid 44912595)
67. Reimer P, Rüdiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106-113.
68. Al-Toma A, Verbeek WH, Visser OJ, et al. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis. 2007;39(7):634-641. (Pubitemid 46888208)
69. Chonabayashi K, Kondo T, Tanaka Y, Ichinohe T, Ishikawa T, Uchiyama T. Sustained complete remission of refractory enteropathy-type T-cell lymphoma following reduced-intensity unrelated cord blood transplantation. Bone Marrow Transplant. 2007;40(9):905-906. (Pubitemid 350020327)
70. Okuda M, Nomura J, Tateno H, Kameoka J, Sasaki T. CD56 positive intestinal T-cell lymphoma: treatment with high dose chemotherapy and autologous peripheral stem cell transplantation. Intern Med. 2002;41(9):734-737.
71. Rongey C, Micallef I, Smyrk T, Murray J. Successful treatment of enteropathy-associated T cell lymphoma with autologous stem cell transplant. Dig Dis Sci. 2006;51(6):1082-1086. (Pubitemid 44127059)
72. Blystad AK, Enblad G, Kvalay S, et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T-cell lymphomas. Bone Marrow Transplant. 2001;27(7):711-716. (Pubitemid 32409445)
73. Prochazka V, Faber E, Raida L, et al. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(1):63-70.
74. Nava VE, Cohen P, Bishop M, Fowler D, Jaffe ES, Ozdemidi M. Enteropathy-type T-cell lymphoma after intestinal diffuse large B-cell lymphoma. Am J Surg Pathol. 2007;31(3):476-480. (Pubitemid 46673123)
75. Tack GJ, Wondergem MJ, Al-Toma A, et al. Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. Bone Marrow Transplant. 2011;46(6):840-846.
76. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as firstline treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316-2323. (Pubitemid 47523150)
77. Soldini D, Mora O, Cavalli F, Zucca E, Mazzucchelli L. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma. Br J Haematol. 2008;142(3):484-486. (Pubitemid 351962178)
78. Kircher SM, Gurbuxani S, Smith SM. CHOP plus alemtuzumab can induce metabolic response by FDG-PET but has minimal long-term benefits: a case report and literature review. J Gastrointest Cancer. 2007;38(1):59-62.
79. Vivas S, Ruiz de Morales JM, Ramos F, Suárez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med. 2006;354(23):2514-2515.
80. Verbeek WHM, Mulder CJJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med. 2006;355(13):1396-1397.
81. Al-Toma A, Goerres MS, Meijer JW, et al. Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol. 2006;4(11):1322-1327. (Pubitemid 44716738)
82. Tack GJ, Verbeek WH, Al-Toma A, et al. Evaluation of cladribine treatment in refractory celiac disease type II. World J Gastroenterol. 2011;17(4):506-513.
83. Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827-5834.
84. Corrao G, Corazza GR, Bagnardi V, et al. Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 2001;358(9279):356-361. (Pubitemid 32739095)
85. Holmes GK, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease: effect of a gluten free diet. Gut. 1989;30(3):333-338. (Pubitemid 19091159)
86. Collin P, Reunala T, Pukkala E, Laippala P, Keyriläinen O, Pasternack A. Coeliac disease: associated disorders and survival. Gut. 1994;35(9):1215-1218. (Pubitemid 24277333)
87. Peters U, Askling J, Gridley G, Ekbom A, Linet M. Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med. 2003;163(13):1566-1572. (Pubitemid 36835101)
88. Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, Collin P. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis. 2006;38(6):374-380. (Pubitemid 44356222)
89. Silano M, Volta U, Vincenzi AD, Dessì M, Vincenzi MD. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci. 2008;53(4):972-976. (Pubitemid 351379816)
90. Olén O, Askling J, Ludvigsson JF, Hildebrand H, Ekbom A, Smedby KE. Coeliac disease characteristics, compliance to a gluten free diet and risk of lymphoma by subtype. Dig Liver Dis. 2011;43(11):862-868.
91. Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut. 2003;52(8):1211-1214. (Pubitemid 36877438)
92. Gao Y, Kristinsson SY, Goldin LR, Björkholm M, Caporaso NE, Landgren O. Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association. Gastroenterology. 2009;136(1):91-98.